These insights have driven early-phase clinical trials (https://clinicaltrials.gov) exploring anti-IRE1 (NCT03950570) and anti-PERK (NCT04834778) compounds as potential cancer therapies86,87. This evidence concerns the gene EIF2AK3 and cancer.